Abstract
Mycobacterial infections and multidrug-resistant (MDR) strains of Mycobacterium generate high mortality, this has triggered the scientific community to search for novel, effective, and safer therapeutics. A series of 4, 5-disubstituted-1, 3, 4-oxadiazole derivatives were screened for mycobacterial activity against H37Rv, MDR and XDR strains. To recognize the mechanism of action of these compounds and to identify their supposed drug target, molecular docking and dynamics studies were employed against DprE1 mycobacterial enzyme, which is reported to be an essential enzyme for mycobacterial growth and survival. The ADME and drug-likeness properties revealed that all the compounds have good pharmacokinetic properties. All the compounds have high affinity towards the enzyme. The newly synthesized derivatives were confirmed through FT-IR, 1 H-NMR, and LCMS. In-vitro microplate alamar blue assay (MABA) to determine the MIC (minimum inhibitory concentration) values against Mycobacterium tuberculosis H37Rv was performed for the synthesized compounds. The synthesized compounds 2A, 3A, 4A, 5A and 6A exhibited promising activity against Mycobacterium tuberculosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
